Newsroom

SELLAS Shares Surge After Phase 3 Leukemia Vaccine Cuts Death Risk by 41%

17 November, 2026   /   News   /  AI   /   Tags:  gps, sellas, vaccine, leukemia, survival

SELLAS Shares Surge After Phase 3 Leukemia Vaccine Cuts Death Risk by 41%

SELLAS Life Sciences stock jumped sharply on Tuesday after its cancer vaccine met the primary overall survival goal in a pivotal Phase 3 trial for acute myeloid leukemia patients

Trial Results Show Meaningful Survival Benefit

SELLAS Life Sciences Group Inc. reported positive topline data from its pivotal randomized Phase 3 REGAL trial of galinpepimut-S, or GPS, an investigational immunotherapeutic vaccine. The study evaluated GPS as maintenance monotherapy against the investigator’s choice of best available treatment in patients with acute myeloid leukemia who had achieved a second or later complete remission, or complete remission with incomplete platelet recovery, following second- or later-line salvage therapy and who were ineligible for or unable to undergo allogeneic stem cell transplantation.

The trial met its primary endpoint of overall survival. GPS produced a statistically significant and clinically meaningful improvement, reducing the risk of death by 41% with a hazard ratio of 0.59 and a two-sided p-value of 0.035. Median overall survival reached 24.0 months for patients receiving GPS compared with 14.7 months for those on best available treatment. The analysis was triggered by a pre-specified threshold of 80 deaths under the statistical analysis plan.

Key REGAL Trial Findings
  • Hazard ratio for death: 0.59 (41% risk reduction)
  • Median overall survival: 24.0 months with GPS vs. 14.7 months with best available treatment
  • P-value: 0.035 (two-sided)
  • Patient population: AML in second or later remission, transplant-ineligible

Safety and Mechanism of Action

GPS was generally well tolerated. The safety profile remained consistent with earlier clinical experience, and no new safety signals emerged. Most treatment-related side effects were mild to moderate, with injection-site reactions the most frequently reported.

The vaccine is an off-the-shelf product licensed from Memorial Sloan Kettering Cancer Center. It targets the WT1 protein, which is expressed across a range of blood cancers and solid tumors. GPS combines four WT1-derived peptides designed to stimulate both CD4+ and CD8+ T-cell responses across multiple HLA types, aiming to attack residual disease and extend remission.

Stock Market Reaction

Shares of SELLAS, which trade under the ticker SLS on Nasdaq, rose sharply on the news. The stock advanced more than 200% at points during the session, with reports of gains exceeding 281% and prices climbing above $28 at times. Earlier in the day, shares traded near $20.87 to $21.14, representing increases of roughly 179% to 183% from the prior close of about $7.47. Intraday prices ranged from a low near $16.76 to a high approaching $24.87, establishing a new 52-week high.

Trading volume was extraordinarily elevated. One report cited more than 57 million shares changing hands against an average volume near 6.9 million, while other accounts described volume exceeding 200 million shares. Short interest stood at approximately 57.1 million shares as of late October, representing about 28% of the float, a factor that may have contributed to the magnitude of the move through covering activity.

Regulatory Path Forward

SELLAS plans to meet with the U.S. Food and Drug Administration to discuss an accelerated filing strategy. The company is preparing a Biologics License Application for potential submission in the first half of 2027. The treatment remains investigational and is not yet approved for commercial use.

In parallel, the company continues development of SLS009, an investigational CDK9 inhibitor also being studied in acute myeloid leukemia, with earlier indications that Phase 2 topline data could emerge later in 2026.

The REGAL results mark a significant clinical milestone for the vaccine in a patient population with limited options after relapse. Further details from the full data set and regulatory discussions will shape the next steps for the program.

Disclaimer
This article was generated by AI using information from multiple industry sources. It has not been reviewed or verified by a human editor and may contain inaccuracies, omissions, or misinformation. Readers are encouraged to independently verify any information before making decisions based on its content.
This article is for informational purposes only and does not constitute financial, legal, or investment advice. Cryptocurrency and related investments involve substantial risk, and past performance does not guarantee future results.